.-G protein-coupled receptors (GPCRs) comprise a large and diverse family of molecules that play essential roles in signal transduction. In addition to a constantly expanding pharmacological repertoire, recent advances in the ability to manipulate GPCR expression in vivo have provided another valuable approach in the study of GPCR function and mechanism of action. Current technologies now allow investigators to manipulate GPCR expression in a variety of ways. Graded reductions in GPCR expression can be achieved through antisense strategies or total gene ablation or replacement can be achieved through gene targeting strategies, and exogenous expression of wild-type or mutant GPCR isoforms can be accomplished with transgenic technologies. Both the techniques used to achieve these specific alterations and the consequences of altered expression patterns are reviewed here and discussed in the context of GPCR function and mechanism of action.
function of an associated intracellular G protein. The most highly conserved regions within this superfamily are the I. INTRODUCTION seven hydrophobic transmembrane segments. The domains of low sequence conservation include the NH 2 and The signaling function of a large variety of hormones, COOH termini and intervening loop regions; GPCR topogneurotransmitters, and even sensory stimuli is mediated raphy places the NH 2 terminus and three intervening loop through G protein-coupled receptors (GPCRs). The large regions on the extracellular surface, with three intervenarray of GPCRs, numbering in the hundreds, represent a ing loop regions and the COOH terminus residing intracelsuperfamily of proteins with both structural and func-lularly. In the case of the bioamine receptors, the ligand tional homology (131) . The GPCR superfamily can be sub-binding pocket is largely formed by the transmembrane divided into three major subfamilies: the rhodopsin/b-ad-helices, whereas many of the peptide and/or glycoprotein renergic, vasoactive intestinal polypeptide (VIP)/secretin, GPCRs also rely on the extracellular loop and NH 2 -termiand the metabotropic glutamate receptor families. A nal regions for binding. The poorly conserved intracellular GPCR transduces signals across the plasma membrane by loops and COOH terminus encode the domains that are interacting with ligand on the extracellular surface and involved in G protein interaction, cellular trafficking, and agonist-induced desensitization. undergoing a conformational change that modifies the In addition to the large diversity of GPCRs, the G ies fail to measure receptor protein levels, which do not necessarily correlate with mRNA levels. Having access to proteins with which they interact also constitute a large family of homologous members (22) , and the demonstra-the cloned receptor also makes it possible to transfect and express GPCRs in cultured cells at high receptor densities, tion that some GPCRs can interact with more than one type of G protein reveals the complexity of signaling possi-thereby permitting more detailed pharmacological analysis, as well as analysis of G protein coupling behavior and bilities (45) . The large host of end-stage effectors modulated by G proteins, such as adenylyl cyclases, phospholi-second messenger generation. Frequently such studies can be performed in heterologous cell types that are null pases, and ion channels, gives rise to the extraordinary range and subtlety of signaling that can be achieved in for that GPCR subtype or any related subtypes, so the information is unequivocal. It should be noted, however, this system.
One of the fundamental issues facing investigators that overexpression of receptors in heterologous cell systems does not always faithfully reproduce normal coustudying GPCRs is the ability to dissect out the mechanistic and functional differences between GPCR subtypes, pling behavior and frequently cannot provide a physiological readout that intact organs, tissues, or whole animals especially among highly conserved members. The ability to do so is critical, for in many cases the need to discrimi-can provide.
Along with the advent of cloning and expression technate between related subtypes can be of therapeutic significance. With a therapeutic approach in mind, there are niques has come the ability to manipulate gene expression in vivo, which represents perhaps the most powerful two interdependent issues commonly addressed. One is to identify the receptor subtype(s) that modulates the method to analyze GPCR function to date. Once a given GPCR gene has been cloned, the technology exists to 1) physiological process in question. The other is to discover ligands that are selective for that receptor or set of recep-delete the gene from the entire genome; 2) delete the gene within specific tissues or in an inducible fashion; 3) tors. Their interdependence derives from the fact that while many ligands have aided in the identification and exogenously express the gene at higher than normal levels or in a tissue-specific manner; 4) express mutant or anticlassification of distinct receptor subtypes, distinct GPCR subtypes that have been identified by other means such sense forms of the receptor, or exchange mutated forms of the receptor gene for wild type counterparts; and 5) use as cloning drive the search for greater selectivity in ligands. From a therapeutic standpoint then, the ultimate GPCR regulatory sequences in conjunction with reporter genes to monitor the developmental and tissue-specific goal is to develop selective agents for each GPCR subtype.
Unfortunately, traditional pharmacological methods patterns of expression. These varied approaches now allow investigators to explore many aspects of GPCR are frequently unsuitable or incapable of discriminating between highly related GPCR subtypes, especially in vivo. function in development and physiology, especially when comparing highly related members. Such techniques also A striking example of this would be the 14 members of the serotonin receptor family (58) , which presumably interact frequently reveal novel or unexpected roles for GPCRs and, in the case of orphan receptors, can be used as an with the same endogenous ligand, but for which only a few selective agents are available. So although subtype-investigative tool to understand their endogenous functions and aid in identification of the natural ligand. selective drugs are an invaluable resource, in many instances either their relative selectivity is poor, the reAlthough such techniques have provided a wealth of information on GPCR function and expression, these apceptor subfamily size is intractably large, or the predominance of receptors in a given target tissue disproportion-proaches are also likely to gain use as tools for drug testing and/or discovery. Thus drugs that are highly subtype ately favors occupation of a nonrelevant subtype.
The ability to clone and express the genes encoding selective should have no effect on mice lacking the gene for that specific subtype. A response to the drug would GPCRs has been instrumental to our understanding of GPCR function and mechanism of action, and has thus indicate interaction with closely related subtypes or even more distantly related subtypes. Furthermore, the ability far succeeded in identifying far more GPCRs than there are natural ligands. In some instances, this has led to the to manipulate GPCR expression in the whole animal has been used to create models of human disease (53, 97, identification of so-called ''orphan receptors'' that possess high sequence conservation to members of the GPCR su-144). Such models can be used to track developmental progress of the disease or to test therapeutic intervenperfamily yet have no identified ligand(s) (99) . Other important properties of GPCR function can be addressed tions. In either case, the ability to manipulate GPCR expression in the whole animal represents an exciting opusing the techniques of molecular biology as well. The spatial and temporal expression pattern of the receptor portunity to both reveal new insights into GPCR mechanism and function, as well as to provide new therapeutic in question can be studied in great detail using in situ hybridization, reverse transcription-coupled polymerase approaches for the treatment of disease. In this review, we will provide specific examples of how the techniques chain reaction, and other mRNA quantitation methods. The disadvantage of these approaches is that mRNA stud-of in vivo genetic manipulation have been used to study GPCR function and discuss the impact they have had on individual mouse lines showing positional effects. The discovery of one such insertional mutant, the chakragati our understanding of GPCR biology.
(ckr) mouse, may prove to be a valuable tool in studying GPCR function. This mouse was serendipitously created II. GENETIC APPROACHES TO STUDY by standard transgenic mouse technology, and the G PROTEIN-COUPLED RECEPTORS transgene appears to have interrupted a locus involved in motor coordination and behavior, affecting brain dopamine receptors (34, 117) . Such transgenic lines can inad-A. Transgenic Techniques vertently provide new tools in the dissection of the GPCR signaling cascade and the genetic influences that lead to The ability to stably introduce genetic material into animals has greatly facilitated our understanding of GPCR proper receptor expression and brain development.
Several transgenic animals have been made to charfunction and mechanism of action. The most frequent method for generating transgenic animals involves micro-acterize regulatory control regions within GPCR genes.
When fused to reporter genes like lacZ or the gene encodinjection of DNA into the male pronucleus of a fertilized mouse egg, transfer of microinjected eggs into pseudo-ing chloramphenicol acetyltransferase (CAT), these regulatory sequences can be used to map spatial and temporal pregnant females, and normal delivery of mice. Some portion of these animals will integrate the injected DNA into GPCR expression patterns. Frequently, such studies are useful for very detailed analyses of GPCR expression patthe host genome, and such founder animals (whose cells are frequently mosaic for the transgene) can transmit the terns, especially when binding or receptor autoradiography lack specificity, but they can also be used to identify integrated product to progeny. Barring any deleterious phenotypic effects, the transgene can then be transmitted novel promoter or enhancer elements that regulate tissue or developmental expression patterns. to subsequent generations in a Mendelian fashion. Such techniques have also been applied to rats, pigs, goats, and Regulatory sequences from the 5-flanking regions of the dopamine D 1A receptor, serotonin (5-HT 2 ) receptor, other mammals (103, 104) , but by far the most frequent recipient is the mouse, due to its short generation time follicle-stimulating hormone (FSH) receptor, and rhodopsin have all been used in conjunction with reporter genes and ease of use. Other techniques to introduce genes into animals include viral infection (146), direct DNA injection to analyze receptor-specific expression patterns in mice (42, 43, 124, 139) . In the case of the D 1A receptor, 6.4 kb (154), or incorporation of genetically engineered cells into host animals or embryos (57) . Each of these approaches of 5-flanking sequence was fused to the lacZ reporter gene, and the pattern of lacZ expression in the brain was has its own particular advantages and disadvantages, as is discussed in section II, A-C, in the context of GPCRs. analyzed in transgenic mice. As a result of the sensitivity of reporter gene assays and the specificity inherent in the The ability to introduce foreign DNA is also accompanied by the ability to specifically manipulate the intro-technique (obviating interference from related receptor subtypes), it was possible to demonstrate that within the duced genetic material. Genes of interest can be fused to any number of tissue-specific, inducible, or globally striatum, lacZ expression was confined to neurons within the matrix, and not in striosomes (124) . Promoter regions expressed regulatory elements in an attempt to localize or specify expression patterns of the transgene. The ex-derived from the 5-HT 2 or FSH receptors fused to the CAT can direct brain-and gonadal-specific expression, pressed gene can be the wild type, the result of site-specific mutagenesis, or represent a chimeric union between respectively (43, 139), whereas various lengths of the bovine rhodopsin promoter fused to lacZ direct rod and cone multiple gene products. The transgene can also be expressed in an antisense orientation to suppress endoge-specific expression (42). As well, GPCR regulatory regions can theoretically provide reagents for cell-or tissue-spenous gene expression. Although the transgenic technique provides a great deal of versatility, there are some aspects cific expression of other gene cassettes. An example of such an approach is the expression of phenylethanolof gene delivery that are problematic. It can be difficult to control transgene copy number. Trangenes are injected amine N-methyltransferase (PNMT) under the control of dopamine b-hydroxylase regulatory sequences, which efas linear DNA fragments that form concatamers of varying lengths before integration into the chromosomal DNA. fectively converts noradrenergic nerve terminals to an adrenergic phenotype (74). Although these reagents are not Moreover, the site of integration of introduced DNA into the genome is frequently nonspecific, and position effects derived from GPCRs themselves, this method can be exploited to study the biosynthetic enzymes involved in cateare not uncommon (111, 160). Such position effects influence transgene expression patterns and can alter the ex-cholamine synthesis, and in turn, GPCR function and be-
havior. Such studies demonstrate that the transgenic techpression of genes near the site of integration. These limitations are frequently addressed by creating and analyzing nique can be useful in characterizing receptor expression patterns with high sensitivity and specificity, but it must several independent lines to provide a spectrum of transgene copy numbers and to eliminate the effect of also be noted that transgene expression patterns can be quite variable when comparing independent lines derived function. A constitutively activated mutant of the a 1b -AR whose expression is targeted specifically to the heart usfrom the same construct. As previously noted, integration site and position effects can influence transgene expres-ing the a-myosin heavy chain promoter shows evidence of cardiac hypertrophy, including increased heart weightsion, sometimes producing expression patterns that are ectopic or incomplete in comparison with the endogenous to-body weight ratios, increased myocyte cross-sectional area, and elevated diacyglycerol content, a hallmark of gene (43) . Thus, for the analysis of GPCR expression patterns, the traditional transgenic technique is now fre-a 1 -AR activation (97) . Interestingly, these animals only overexpress the mutant a 1b -receptor by Ç3-fold over norquently supplanted by gene targeting techniques (see sect. IIC), which possess higher fidelity for proper expression mal levels, whereas two independent studies of transgenic mice expressing the wild-type a 1b -receptor at Ç20-to 50-patterns in vivo.
Overexpression of nonmutated GPCRs in transgenic fold above normal levels show no evidence of hypertrophy (W. Koch and H. Rindt, personal communication). The animals has been useful in characterizing the mechanism(s) of receptor activation, as well as the functional creation of a heritable model of cardiac hypertrophy can be exploited to dissect the molecular pathways of the consequences of receptor overexpression. Overexpression of the human b 2 -adrenergic receptor (AR) spe-hypertrophic response, whereas the failure of wild-type a 1b -receptor to induce hypertrophy demonstrates subcifically targeted to the hearts of mice using the a-myosin heavy chain promoter has profound effects on cardiac type-specific differences in basal GPCR coupling behavior (in contrast with b 2 -AR, b 1 -AR, and A 2 transgenics). function. In the absence of b-AR agonist, heart rate, dP/ dt max , and adenylyl cyclase activity are elevated to levels A naturally occurring polymorphism in the human b 2 -AR (T164I) has also recently been used to create comparable to those observed in wild-type mice after maximal stimulation with isoproterenol. In the b 2 -AR transgenic mice overexpressing the b 2 -AR receptor specifically in the heart, again using the heart-specific a-myotransgenics, there is little additional stimulation of these parameters by isoproterenol (96) . These results suggest sin heavy chain promoter (144). Similar to the original b 2 -AR transgenic (96), overexpressed wild-type b 2 -ARs also that b 2 -ARs can couple to chronotropic and inotropic responses in the heart, and also demonstrate that persistent result in enhanced cardiovascular function, whereas mice with the overexpressed mutant b 2 -AR in comparison disb 2 -AR signaling can occur in the absence of agonist. The same transgenic line was later used as a model to test the play impaired cardiac function (144). These findings are interpreted to suggest that this polymorphism may have theory of inverse agonism, and the results were used to provide support for the two-state model of GPCR activa-pathophysiological consequences in humans. Although both transgenic approaches have taken the b 2 -AR out of tion (13). In this case, the transgenic model provided a convenient platform to test both receptor function and its normal cellular context, both studies nonetheless provide valuable information regarding GPCR function and theory.
Atrial-specific overexpression of the cloned human coupling behavior. Transgenic techniques are most often used to overexb 1 -AR has also been achieved in mice (11) and, similar to the b 2 -AR transgenic model, shows evidence of constitu-press a component of a signaling pathway; however, they can also be used to overexpress modified, nonfunctional tive signaling in the absence of agonist. In contrast to the b 2 -AR overexpressors, however, basal and stimulated proteins that can compete with and suppress the activity of endogenous proteins. This ''dominant negative'' apadenylate cyclase in b 1 -transgenics is actually lower than the wild-type counterparts (91) and suggests that b 1 -and proach was used to examine the importance of the badrenergic receptor kinase (b-ARK) on cardiac b-receptor b 2 -AR coupling mechanisms may be quite distinct.
Transgenic mice in which the thyroglobulin promoter function by creating mice that overexpressed either b-ARK or a b-ARK inhibitor (b-ARK i ). The b-ARK i is a nonwas used to direct expression of the adenosine A 2 receptor specifically to the thyroid displayed glandular hyper-functional competitor of b-ARK activity derived from the COOH terminus of b-ARK itself. The cardiac-specific explasia and severe hyperthyroidism, eventually leading to premature death (81). These data suggested that A 2 recep-pression of these genes resulted in attenuated b-AR agonist signaling in the case of b-ARK and a basal entor overexpression can lead to constitutive signaling and that some naturally occurring thyrotropin receptor mu-hancement of cardiac contractility in the case of b-ARK i , elegantly demonstrating the importance of in vivo desensitants (like the A 2 receptor, coupled to G s a) could cause hyperfunctioning thyroid adenomas (112). These mice tization mechanisms on heart function in both basal and stimulated states (76) . could be valuable animal models for studying hyperfunctioning adenomas and provide further evidence for the The application of the transgenic technique has been particularly fruitful in studying the mechanism of rhodopmitogenic properties of some GPCRs (reviewed by van Biesen, Ref. 145).
sin signal transduction and the molecular basis of heritable visual disorders. A number of studies have been able The creation of transgenic mice bearing engineered mutations in GPCRs has also been used to study GPCR to recapitulate the phenotype of the human disease retini-tis pigmentosa (RP) by expressing transgenes with analo-specific delivery is usually not regulatable. Tissue-specific viral delivery has been reported (69) , and a promising gous mutations to those commonly found in RP patients (20, 41, 57, 83, 105, 106, 110, 114, 119, 134, 151) . These approach for the future is exemplified by the experiments of Federspiel et al. (32) , who showed that tissue-specific studies have effectively documented the aberrant signaling properties and accelerated photoreceptor cell degen-expression of the avian leukosis virus (ALV) receptor rendered the expressing tissue susceptible to ALV infection. eration associated with various rhodopsin mutants. As one would expect, many of these studies show positive A transgenic method for circumventing DNA microinjection can be used in early mouse embryos that express the correlations between transgene dose and severity of disease (57, 83, 110) . Specific mutations in rhodopsin have tv-a receptor (the receptor for subgroup A avian leukosis and sarcoma viruses), rendering them susceptible to ALV also been created to examine the role of phosphorylation and desensitization in the visual signaling cascade, provid-infection (33). Novel delivery methods such as these will undoubtedly enable researchers in the future to tailor deing important information on the role of desensitization in GPCR signaling (41). As well, detailed mechanisms of livery methods to their respective needs. the retinal degeneration have been investigated, including one study in which chimeric mice were created by aggre-B. Antisense Techniques gation of wild-type embryos with embryos from transgenic mice expressing mutant rhodopsin (57) . DeThe use of antisense approaches to reduce or elimispite the chimerism, these studies showed uniform retinal nate the expression of specific genes was initially reported degeneration, suggesting that the retinal degeneration asover 10 years ago (66) . While the basic goal remains the sociated with the RP phenotype is not limited to the genetsame, the technical repertoire has been expanded and ically altered photoreceptor cells. Together with other refined to make the technique feasible for in vivo work. transgenic studies, these results have allowed investiga-In some instances, this approach can provide as much or tors to invoke a disease model whereby mutant rhodopsin more information than transgenic or knockout techniques undergoes abnormal cellular trafficking, triggering accel-at a substantial savings in cost and time. Furthermore, erated cellular apoptosis. many of the genetic approaches such as those using Although traditional transgenic techniques are widely transgenic or knockout technology are limited in their applicable, in some instances this method of gene delivery animal host range (most frequently using the mouse), is inappropriate, such as when excess copy numbers of whereas in theory, many of the current antisense technolthe transgene or manipulation of the genome have delete-ogies are applicable to virtually any species and can be rious consequences. Transgenic strategies for single-copy, applied at various developmental stages. One major disadsite-specific integration of genes have been developed vantage of the antisense approach, however, is its empiri- (17) , and the advent of inducible transgenes now allows cal nature. Optimizing the region and length of antisense for graded and precise control of transgene expression. homology can be problematic and must be determined by Examples of such inducible systems include the Tet-trans-trial and error. activator (35, 71) and ecdysone inducible systems (108).
The capacity to reduce expression using antisense Although such inducible systems have not yet been ap-can derive from several different mechanisms. Central to plied to GPCRs, the ability to regulate the timing and all of these is the specific base-pair interactions between degree of transgene expression will extend the range and the target and the antisense probe. In the case of plasmid power of experiments directed at the analysis of GPCR or viral expression systems that express antisense RNA, behavior. This is particularly true when the developmental loss of expression can occur when RNA-RNA hybrids are role of a given GPCR is being studied, since the timing degraded by endogenous double strand-specific riboof transgene expression is under direct control by the nucleases (RNases). In the case of antisense inhibition investigator.
by oligodeoxynucleotides, the RNA-DNA hybrid can be Viral delivery methods can also be used to express degraded by RNase H. There are also examples of oligonuforeign genes, and there are a variety of vectors and meth-cleotides invading chromatin DNA, forming triple helices, ods available (10, 47, 126, 153) . Although use of viral deliv-or causing translational arrest [for recent reviews, see ery methods to the study of GPCRs has been carried out Crooke and Bennett (26) or Albert and Morris (4)]. In all (62), such approaches have not been widely exploited. of these instances, a critical balance is struck between Clearly, the ability to deliver and express GPCR genes at the extent to which expression is repressed and the speciselected times during the development of the animal is ficity for a single gene product. The extent of repression advantageous. Attempts to couple such delivery systems is governed by the abundance of antisense probe relative with a tissue-specific component is also a worthwhile to the target mRNA and appears to require Ç20-fold exgoal. Most transgenic strategies attempt to direct tissue-cess for antisense RNA, and several hundredfold excess specific expression in some fashion, and although some for oligonucleotides (4, 52, 66). At extremely high levels of antisense probe, specificity will be lost by cross-hybridviral infection mechanisms display tissue tropism, tissue-ization to related targets, although such losses in specific-tion of receptor expression is not complete. Moreover, ity can be mitigated by designing antisense probes to from a mechanistic standpoint, it also suggests that there unique, nonconserved regions of the gene to avoid cross-is little or no reserve of surplus receptors in dopamine hybridization.
receptor signaling. This is also apparent in gene knockout Early applications of antisense technique frequently experiments where heterozygous mice can be distinused expression vectors to produce antisense transcripts guished from wild-type mice (8). from (usually) large fragments, and although still in use,
The full complement of known opiate receptors this technique has been more recently replaced by the (ORs) has also been targeted by antisense strategies. An use of antisense oligonucleotides. The finding that short antisense-directed reduction in brain d-, k-or m-subtypes synthetic oligonucleotides (15-50 nt) can 1) suppress ex-is accompanied by decreases in locomotor hyperactivity pression via antisense mechanisms and 2) gain entry to and/or antinociceptive effects induced by receptor subcells in vitro or in vivo without the need for complicated type-specific agonists (2, 12, 21, 101, 140, 141). Similar transfection or infection protocols make it an ideal choice to the a 2 -adrenoceptor and dopamine receptor antisense for many investigators. The use of more stable phosphoro-experiments, antisense effects on opiate receptor expresthioate oligonucleotide derivatives to avoid loss of probe sion are reversible after cessation of oligonucleotide delivfrom nuclease digestion has become almost standard ery. Additionally, antisense inhibition of d-ORs has been practice (26, 168). The use of catalytic antisense ribo-achieved through an intrathecal administration route, zymes has also gained favor recently as an antisense strat-blocking the action of intracerebroventricularly adminisegy to reduce protein expression (128) .
tered b-endorphin (140) . The power of the antisense apDirect injection of antisense oligonucleotides into the proach is exemplified by experiments that demonstrate brain has become a popular tool in the study of GPCR that antisense oligonucleotide directed against d-OR preffunction. There are many examples of its use to delineate erentially blocks the antinociceptive effects to a putative the role of specific GPCR subtypes in various behaviors d 2 -OR agonist, but not a putative d 1 -OR agonist, while antior physiological properties. For instance, when antisense sense directed against a conserved region shared by all oligonucleotides directed against a 2 -adrenoceptor subtypes three known opioid receptors can block the effects of a and c were injected into the locus ceruleus of the rat, the d-, m-, and k-OR agonists (including both d 1 -and d 2 -agohypnotic response to the a 2 -specific agent dexmedetomi-nists) (12). These results have been interpreted to suggest dine was specifically blocked only in a 2a -antisense-treated that multiple d-OR subtypes exist, a conclusion that would rats and unaffected in a 2c -treated rats. Furthermore, sensi-be difficult to make on pharmacological grounds alone. tivity to dexmedetomidine could be recovered in a 2a -antiAntisense inhibition of angiotensin II type 1 (AT 1 ) resense-treated rats after cessation of treatment (100) .
ceptors has also been carried out and has effectively shown In the case of brain dopamine (D) receptors, three that the hypertensive effects of angiotensin II are mediated known subtypes have been targeted by antisense strate-by AT 1 receptors in the central nervous system (48) as well gies, and in virtually all examples, antisense reduction in as by AT 1 receptors in vascular smooth muscle and the dopamine receptor expression is limited to the targeted adrenal gland (65) . In both cases, antisense inhibition of subtype. The D 1 receptor antisense treatment results in AT 1 expression had preferential effects on spontaneously decreased D 1 agonist-induced grooming behavior and D 1 hypertensive rats, raising the possibility that hereditary or agonist-induced rotational behavior of lesioned mice, congenital alterations in the renin-angiotensin system rewhile leaving unaffected the stereotyped behavior in-sulting in hypertension may be treatable by an antisense duced by D 2 agonists (163) . Likewise, antisense treatment approach. Interestingly, Iyer et al. (65) were able to show of D 2 receptors in rats (162) or mice (115, 165) results that one-time, systemic delivery of a retroviral construct in specific loss of D 2 receptors and reduced D 2 agonist-expressing AT 1 receptor antisense was able to suppress AT 1 mediated locomotor and grooming behaviors, with no al-expression and lower blood pressure up to 73 days after terations in D 1 agonist-induced behaviors (162, 165) . Ef-delivery. The AT 1 receptor antisense oligonucleotides have fects could also be seen in the absence of agonist treat-also been used to demonstrate the dipsogenic role of this ment on spontaneous locomotor activity and cataleptic subtype in rats (121) . The data gained from antisense apbehavior (162) . Antisense inhibition of D 3 receptors has proaches to study angiotensin receptors point to the general revealed a possible role for this subtype in the mediation advantages and disadvantages inherent in oligonucleotide of dopamine synthesis (107). These experiments are par-or transgenic delivery strategies. Although oligonucleotideticularly informative, since a high degree of specificity based methods are titratable and reversible, they must be could be achieved for each knockout. Interestingly, in regularly or continuously administered. Viral or transgenic these experiments, the reduction in dopamine receptor delivery of antisense, on the other hand, is more persistent, density varied from 19 to 48%, but in all cases, a phenotype but less regulatable. could be observed. This suggests that the antisense techIn addition to the ability of antisense strategies to control hypertension, recent experiments have also demonnique can provide useful information even when disrup-strated a convincing antisense effect on another clinically the study of GPCR function in physiology, development, and behavior. The essence of gene targeting is that once relevant model, that of bronchial asthma (109). These investigators showed that delivery of aerosolized phosphorothio-a gene has been cloned, the technology exists to alter its endogenous counterpart within the mouse, either by ate antisense oligonucleotides directed against the adenosine A 1 receptor provided significant protection against disruption, deletion, site-specific mutation, or exchange for another gene product. The technique relies on the adenosine and allergen challenges. This antisense treatment was able to significantly reduce adenosine receptor density ability of modified cloned DNA introduced into mouse embryonic stem cells to undergo homologous recombinain airway smooth muscle, suggesting the route of administration is a viable one for antisense treatment and that direct tion with the host genome, thereby replacing the endogenous gene with the modified DNA (19) . replacements, or what the role of a particular gene prodprovided evidence for subtype diversity in this receptor family. Antisense inhibition of this receptor led to a loss of uct is within a given tissue or at a specific developmental stage. The use of gene targeting to study GPCRs has been gastrin-induced acid secretion in the stomach but had no effect on CCK-8-induced acid secretion (116).
widely exploited and has provided many insights into the function of GPCRs and their mechanism of action. Despite the broad range and utility of the antisense approach, there are examples of nonideal behavior or alOne of the most frequent forms of gene targeting involves replacement of a given gene with an insertionally ternative mechanisms for antisense action (26). For instance, constant intravenous infusion of neuropeptide Y-inactivated counterpart. Gene ''cassettes'' that contain antibiotic resistance genes under control of strong en-Y 1 receptor antisense oligonucleotides resulted in a modest reduction in the vasoconstrictor response to neu-hancers are inserted within the coding region of the desired gene, thus disrupting normal expression. The casropeptide Y in rats, whereas the ''sense'' oligonucleotide control actually resulted in exaggerated neuropeptide Y sette can also code for reporter genes such as lacZ, CAT, or green fluorescent protein. In many instances, the casresponses (133) . Likewise, antisense inhibition of vasopressin V 1 receptor resulted in specific deficits in arginine sette is inserted into a single convenient restriction endovasopressin-induced social memory tasks and anxiety-re-nuclease site within the gene of interest, preserving all of lated behavior as expected, whereas mRNA levels for this the upstream and downstream flanking sequences; in receptor actually increased after antisense treatment. Like other instances, the cassette replaces a deleted region of the neuropeptide Y-Y 1 antisense experiments, the sense the gene to be targeted. The latter strategy is frequently oligonucleotide-treated animals also showed phenotypic used when there is a possibility that partial translation changes, distinct from those of random oligonucleotide-products of the targeted gene can be functional, or when treated animals (80).
functional product can be produced by an RNA splicing Although low cost and ease of use are attractive bene-event that skips over the disrupting cassette. The inclufits of this technique, they must always be weighed against sion of reporter genes within the targeting construct the potential confounding factors mentioned above. De-serves a dual purpose: 1) to disrupt the gene of interest spite such shortcomings where specificity and degree of and 2) to allow for assessment of receptor expression knockout can be problematic, antisense techniques re-patterns. The inclusion of the reporter within the recepmain extremely useful, especially in situations in which tors normal chromosomal context also helps to ensure germ line deletion is lethal or when specific organs like that all of the pertinent regulatory information is present, the brain or lungs are to be targeted. Expression of GPCRs which is not always a certainty in standard transgenic may be particularly amenable to antisense inhibition given reporter constructs that contain limited amounts of reguthe low level at which most subtypes are expressed and latory information. In some instances (24, 93) , the reporter the fact that phenotypic changes can be seen with only gene has been fused in-frame with the endogenous gene modest reduction in GPCR levels.
so that the reporter gene contains the essential information for proper subcellular localization.
C. Receptor Knockout Techniques
Examples of GPCR knockouts are listed in receptor families. The use of reporter genes in conjunc-intervening sequence between the recognition sites. The targeted gene having loxP sites (referred to as the ''floxed'' tion with disruption schemes has been demonstrated for the mGlu1 receptor (24) and the AT 1A receptor (93, 132) , locus) is present in all cells of the body throughout development, and the loxP sites are placed such that expression and in addition to characterizing the phenotype of the disrupted gene, has enabled the researchers to localize of the floxed gene is unaffected. The tissue-specific targeting is achieved by tissue-specific expression of cre, the organs and cell types normally expressing these receptors. Matsusaka et al. (93) used ES cells in which both which will mediate excision of the floxed sequence only in those cells in which cre is expressed. By these means, AT 1A receptor alleles were disrupted, and by making chimeras between these targeted cells and wild-type embryos the gene of interest will remain and be functional in all non-cre-expressing cells, but will be lost in cre-expressing were able to show localized, chimeric expression of lacZ in a subset of juxtaglomerular cells. Despite the regional cells. The first in vivo application of this technique was to tissue-specifically target the DNA polymerase b gene expression pattern of lacZ in these chimeric mice, renin synthesis was uniformly elevated (in proportion to the (polb) within the T-cell lineage. The original intent of the experiment was to study the role of polb in T-cell gene extent of chimerism) in all juxtaglomerular apparatuses, whether predominantly composed of knockout or wild-rearrangement, but whole body knockouts resulted in lethality, so alternative strategies were required to study type cells. These results enabled the authors to argue against the role of local angiotensin in the feedback regu-the role of polb in T cells. The floxed DNA polb was specifically excised in T cells by mating mice carrying a lation of juxtaglomerular renin synthesis, in an elegant application of knockout technology.
floxed DNA polb to mice that expressed a cre transgene only in T cells (44) . Although this technique has not been There are also instances of gene targeting in which total gene disruption is not desirable, as in the case where applied to a GPCR as of yet, it was used to demonstrate the critical role of hippocampal N-methyl-D-aspartate one wants to test the function of subtle mutations or alterations in receptor sequence. An early application of this (NMDA) receptors in spatial memory. The NMDA receptors have long been implicated for their role in long-term technique, known as ''hit and run'' was first applied to a hox gene member (49) , but has subsequently also been potentiation (LTP) and memory processes, with specific emphasis on their role within the hippocampus. A specific applied to a GPCR family member, the a 2a -adrenergic receptor (90). The technique depends on the ability to insert test of this idea was recently carried out using the Cre/ loxP system, where transgenic mice that were restricted the mutated version of the gene into the endogenous gene locus by a single homologous recombination event, re-in their expression of cre only to the CA1 region of the hippocampus were used to target floxed NMDA receptor sulting in a tandem arrangement of the mutated gene and the endogenous gene. A second homologous recombina-genes only in that brain region (142). These mice displayed deficits in CA1 synaptic LTP as well as impaired tion event results in excision of the wild-type gene, leaving behind the mutated version. Although effective, more re-spatial memory (143) . This very model system may be of use to those studying the role of GPCRs in memory cent advances such as two-step gene targeting (7, 130, 155) or plug-and-socket (28, 82) can achieve the same mechanisms, because both mGlu and b-AR have been implicated to play roles in hippocampal LTP as well (3, 24, result more efficiently. These more recent advances allow for a more convenient targeting and selection procedure, 56, 68). Theoretically, mice harboring floxed mGlu and/or b-adrenergic receptors could be mated with the existing which in turn makes it easier to analyze more receptor mutants. In either case, these exchange techniques repre-transgenic mouse line expressing CA1-restricted cre. Such studies would allow for a molecular dissection of recepsent a very powerful approach to the study of GPCR function and mechanism of action.
tors involved in hippocampal LTP. As a general technique, once a cre-expressing transgenic is developed and characterized, it can be used to explore the relative importance 2. Tissue-specific and inducible knockouts of any gene product within the expressing tissue, as long as the gene of interest can be floxed without loss of funcIn all of the examples mentioned thus far, gene disruption is carried through the germline; that is, all cells tion.
A related technique is inducible gene targeting. This of the body contain the targeted allele through all stages of development. There are many situations that call for enables the researcher to effect the desired genetic change at any point in development, merely by the addieither a tissue-specific gene targeting or a developmentally timed targeting event, both of which are now feasible. tion of an inducer substance.
The technique is highly analogous to the tissue-speIn the currently applied version of tissue-specific targeting, the initial gene modification involves targeted in-cific gene targeting, although in this case cre expression is under the control of an inducible promoter rather than sertion of loxP (locus of crossing over) recognition sites for the cre (causes recombination) recombinase enzyme, a tissue-specific promoter. An application of this technique was carried out using cre under the control of an which recognizes these sites and mediates excision of the / 9j07$$ja01
12-02-97 15:47:45 pra APS-Phys Rev interferon-responsive promoter, again to effect knockout There are also instances of multiple laboratories independently targeting the same GPCR and failing to find of DNA polb (78) . Other modes of induction are also being developed (164) . similar phenotypes. For instance, D 1 dopamine receptor knockouts have been found to either display increased A caveat to both the tissue-specific and inducible systems is the penetrance of the knockout. Because both locomotor activity (158) or no changes in locomotor activity with increased rearing behavior (29) . Although both protocols rely on cre expression, this enzyme must be expressed in every cell that is to be targeted. Indeed, knockout models show evidence of growth retardation, the severity of this phenotype is much greater in the latter there is evidence from both of these systems that targeted excision does not occur in all cells for which it is intended study, leading to postnatal death unless special feeding regimens are employed. Likewise, the effect of disrupting (44, 78) , and in the case of the inducible system, tissuespecific differences in excision efficiency are found (78) . the expression of the metabotropic glutamate receptor mGluR1 on LTP is controversial. Although attenuation of When receptor systems that serve to amplify signals, or in turn transmit signals to other cells (as GPCRs do), are LTP in the CA1 region of the hippocampus was observed in one study (3), another independent mGluR1 knockout considered, this issue must be carefully considered when interpreting experimental results. Regardless of the cur-showed no change in CA1 LTP (24) . Conversely, the latter study could demonstrate reduced mossy fiber LTP, which rent shortcomings, however, these techniques will undoubtedly be instrumental in furthering our understanding could not be demonstrated for the other mGluR1 knockout (56) . Many of these differences could be attributed to of GPCR function.
strain heterogeneity as mentioned above, although both of these knockouts have been analyzed on 129-C57Bl/6 3. Factors influencing interpretation of hybrids. Other possible explanations for differences in knockout experiments phenotype involve differences in the methods of gene disruption. Has the coding sequence of the targeted gene Despite the widespread use of knockout technology, there are several issues that warrant consideration when been deleted or just interrupted? Where within the coding sequence is the gene disrupted? What type of selection/ interpreting results from such experiments. The first is that many receptor systems have the potential to exhibit reporter gene cassette was used? What is the orientation of the selection/reporter gene cassette relative to the tarplasticity so that lack of one receptor type can be compensated for by up-or downregulation of other receptors geted gene? All of these issues are potential factors that can influence the ultimate phenotype of a knockout involved in that signaling cascade. The second concerns the variability within common mouse strains. The vast model. Disruption of a gene's coding sequence does not necessarily ensure that expression of the disrupted gene majority of ES cell lines that are used for gene targeting and subsequent chimera generation are derived from the is fully extinguished. Disruption of the muscle creatine kinase gene can result in a ''leaky'' knockout (148, 149). 129 mouse strain. This strain is known to possess certain behavioral and functional deficits, breeds poorly, and is Although such leakiness has not been directly demonstrated for a GPCR knockout to date, it must be considdisease prone. The most frequently adopted approach has been to backcross the mutant chimeric animals to a differ-ered as a possible explanation for the occurrence of phenotypic variability within knockouts of the same gene. ent mouse strain, in most cases C57Bl/6. Subsequent intercrossing of 129-Bl/6 hybrids to generate knockout animals The information in Table 1 includes the strategy employed in receptor gene disruption, which in some cases may can create problems due to genetic nonuniformity between controls and knockouts, especially in the genomic explain why the knockout phenotype is either unexpected or differs between investigators. regions surrounding the targeted allele that will be predominantly 129-derived sequence. Several examples of strain-specific differences in phenotype have been noted III. NEW INSIGHTS INTO G PROTEIN-COUPLED for gene-targeted mice (125, 138) and have also been de-RECEPTOR FUNCTION: ILLUSTRATIVE scribed for targeted GPCRs (118). Particularly troubling EXAMPLES is the plethora of behavioral phenotypes observed in genetargeted mice, including several GPCR knockouts, which are reminiscent of the defects noted for the wild-type 129 A. Endothelin Receptor strain [for recent review, see Gerlai (38) ]. Strategies to reduce the strain-specific contributions such as repeated Transgenic and knockout experiments have yielded a great deal of useful information about the function and back-crossing, gene rescue, inducible knockouts, or development of non-129-derived ES cells have been proposed physiology of GPCRs. In many cases, the results confirm or clarify results obtained using pharmacological apto reduce or eliminate these variables, and efforts in these areas will undoubtedly improve our interpretation of proaches. However, there are several examples of knockout or transgenic experiments yielding unexpected or knockout results. novel findings. These results have revealed new therapeu-C. a 2 -Adrenoceptors tic targets for some GPCRs and have provided insight into new modes of receptor signaling. An elegant example of
The a 2 -adrenergic receptors (a 2 -AR) consist of three the way in which knockout experiments can uncover highly homologous family members (a, b, and c). The novel roles for GPCRs is illustrated by the genetic disrup-three a 2 -receptor subtypes couple to the same G proteins tion of the endothelin B (ET B ) receptor. Since their discov-and have similar pharmacological profiles, making it difery in 1988, investigators have primarily focused on the ficult to determine the functional role of each subtype in role of endothelins and their receptors in blood pressure vivo. Gene targeting techniques have now been applied regulation and their potential role in the pathophysiology to all three a 2 -AR subtypes, advancing our knowledge of of hypertension, stroke, and heart disease (120). Disrup-their function and providing new impetus for developing tion of the gene encoding the ET B receptor, however, re-better subtype-selective agents (87, 88, 90). As outlined in sults in a phenotype identical to the long-known mouse Table 1 , the cardiovascular effects of disrupting the genes mutant piebald-lethal (s l ), which may have a human corre-encoding a 2 ARs a, b, and c are quite distinct. From these late in the hereditary form of Hirschprung's disease (55) . studies, it has been suggested that the a 2a -AR is the priSurprisingly, the primary phenotypic observation among mary a 2 -AR responsible for the clinically beneficial hypothese ET B mutants is a perturbation in the function of tensive effect of a 2 -AR agonists in the control of hypertenneural crest-derived cell lineages, manifested in coat color sion, whereas the a 2b -AR subtype is largely responsible spotting and megacolon. These findings were not pre-for the peripheral hypertensive effect of a 2 -AR agonists. dicted based on pharmacological studies and demonstrate Although disruption of a 2c -ARs failed to produce any hethe utility of this approach in identifying the role of spe-modynamic effects in mice, other studies provide evicific GPCRs in development. The ability to deliver pharma-dence that this subtype does play a subtle role in modulatcological agents in utero can be difficult, especially if sub-ing other processes (122). Function of a 2c -AR was studied type selectivity is desired, and knockout strategies may in wild types, a 2c -AR knockouts, and transgenic mice overin some cases be the only means to definitively ascertain expressing the a 2c -AR by approximately threefold under the role of a given GPCR in development or early signaling the control of the natural promoter. This study demonevents.
strated that the hypothermic effect of a 2 -agonists was dependent on a 2c -AR gene dosage, such that knockouts displayed a reduced hypothermic effect and transgenic overexpressors displayed an enhanced hypothermic effect B. Thrombin Receptor compared with wild types after administration of the a 2 -agonist dexmedetomidine. This study also showed an a 2c -AR gene dose-dependent effect on levels of the dopamine Disruption of the gene coding for the cloned throm-metabolite homovanillic acid in the brain. The use of bin receptor revealed several unexpected results. Like the knockouts and transgenics to modulate gene dosage has ET B receptor knockout, mice lacking the cloned thrombin also been effectively applied to study the hemodynamic receptor (tr) show developmental abnormalities, resulting effects of angiotensinogen (70). in significant lethality around embryonic days 9-10. Perhaps most surprising was the observation that the absence D. b 1 -Adrenoceptors of this receptor had no effect on bleeding time, thrombindependent platelet aggregation, or ATP secretion (23) . The cloned receptor that was used to engineer this knockIn the case of b-ARs, knockout of the b 1 -AR was used out possesses a pharmacological profile that matches to show that this subtype is solely responsible for the quite closely the profile which alters platelet function, chronotropic and inotropic effects of nonspecific b-AR so it came as some surprise that these functions were agonists in the heart (Table 1) (118). Traditionally, it had preserved in thrombin receptor knockouts (tr 0/0 ). It was been believed that both b 1 -and b 2 -ARs were coupled to also observed that fibroblasts but not platelets from the these responses in vivo, since both subtypes are extr 0/0 mice were deficient in thrombin receptor signaling. pressed in cardiac myocytes and conduction tissue, and As a result of these findings, the authors concluded that both subtypes are known to couple to adenylate cyclase a second thrombin receptor exists and is important in stimulation. The b 1 -AR knockout studies showed, howmouse platelet function. This type of study is in many ever, that the b 2 -ARs that were expressed in the heart ways typical of the results that can be obtained from could neither couple to adenylate cyclase nor mediate knockout experiments: it both reveals a new and unex-chronotropic or inotropic responses. This is somewhat pected role for the gene in question and provides indirect unexpected in light of transgenic experiments mentioned evidence for the existence of other signaling components above. In transgenic mice that overexpress b 2 -ARs speacting in the same pathway.
cifically in the heart, the overexpressed b 2 -ARs have been / 9j07$$ja01 12-02-97 15:47:45 pra APS-Phys Rev shown to couple to adenylyl cyclase stimulation as well tially and temporally control the delivery of oligonucleotides, expression of transgenes, or excision of gene fragas positive chronotropic and inotropic responses. In these transgenic experiments, however, the b 2 -ARs are ex-ments will only add to the power and subtlety of these techniques to more clearly define mechanisms of action pressed at Ç50-200 times their normal level (96, 144) . Although these transgenic experiments clearly demon-and function of GPCRs. strate that b 2 -ARs can couple to these responses in cardiac myocytes, the b 1 -AR knockout experiments demonstrate F. Modification of Genes Associated with that they do not do so when expressed at physiological G Protein-Coupled Receptor Signaling levels. This conclusion is also supported by studies that have shown that cardiac b 2 -ARs couple to inhibitory, pertussis toxin-sensitive G proteins (156) . The ability to maAlthough the experiments and techniques described here have focused on GPCRs themselves, there is a large nipulate b-AR gene expression in vivo by multiple independent means has thus allowed for a revised model of body of work using similar technical approaches to examine other components of the GPCR signaling cascade. b-AR coupling behavior that was originally based solely on pharmacological data. The results from the b 2 -AR These studies have been instrumental in defining important control points in signaling such as ligand specifictransgenic mice also led to the suggestion that gene therapy with b-ARs may be a future therapeutic goal for vari-ity, the role of transport/reuptake systems, and receptorassociated proteins involved in signaling or desensitizaous models of heart failure (96) . Although this does not fully agree with the majority of clinical evidence sug-tion. Linking the results of such studies to those of the GPCRs themselves is critical to developing a comprehengesting that b-AR antagonists are beneficial in the treatment of heart failure (30, 39, 50) , the ability to effect long-sive model of GPCR function.
The use of transgenic and knockout models targeting lasting physiological changes through defined manipulations of GPCR expression suggests that gene therapy the enzymes involved in catecholamine biosynthesis has been particularly informative in dopaminergic and adrenaimed at some component(s) of the GPCR signaling cascade may be a viable therapeutic approach for the treat-ergic signal transduction mechanisms. Mice lacking the tyrosine hydroxylase (TH) gene fail to synthesize any catement of some diseases.
cholamines (73, 167), whereas mice lacking the gene encoding dopamine b-hydroxylase fail to synthesize norepi-E. Applying Different Methods to the nephrine or epinephrine (137) . The ability to mate mice Same Receptor lacking the TH gene with transgenic mice expressing TH only in noradrenergic cells allows for the creation of mice deficient only in dopamine synthesis (166) , whereas Functional studies on other GPCRs have also benefited from the use of multiple methods to regulate gene transgenic mice expressing PNMT under the control of the dopamine b-hydroxylase gene promoter convert norexpression. In addition to the aforementioned studies on the a 2 -ARs, the angiotensin II receptor AT 1 has been tar-adrenergic nerve terminals to adrenergic nerve terminals (74). Likewise, the role of neurotransmitter reuptake in geted by gene disruption as well as antisense oligonucleotides and retroviral antisense expression vectors (6, 64, GPCR function has been addressed by the disruption of the gene coding for the dopamine transporter (40) . 65, 93, 121, 132) . In all cases, inhibition of AT 1 expression led to decreased blood pressure. More specifically, this Transgenic or knockout animals have also been created to alter the expression of other GPCR ligands such could be achieved by either total gene disruption, systemic antisense gene delivery, or intracerebroventricular as the endothelins (79, 86), angiotensinogen (70), agouti (72, 77, 98, 152) , and neuropeptide Y (31). Effectors of injection of antisense oligonucleotides. In the case of dopamine receptors, the D 1 , D 2 , and D 3 subtypes have been signal transduction downstream of GPCRs in the signaling cascade such as G s a (37), b-ARK (76, 67) , and the cyclic targeted by antisense oligonucleotides as well as gene knockouts, and although the studies on D 1 and D 3 recep-nucleotide-gated cation channel (18) have also been specifically altered, and all have significantly impacted our tors did not perform analogous tests, both the D 2 receptor knockout as well as D 2 antisense experiments found a models of GPCR function and mechanism of action.
The ability to mate mice bearing distinct genetic motor impairment upon loss of receptor (8, 115, 162, 165) . Likewise, either genetic ablation or antisense treatment of alterations represents perhaps one of the most intriguing prospects for the future. G protein-coupled receptors the m-opioid receptor results in loss of morphine-induced analgesia (21, 94, 129) . Given the caveats inherent in either with redundant functions can be revealed by creation of double knockouts, and in the case of knockout lethality, transgenic, knockout, or antisense experiments, the ability to combine the results from such disparate approaches gene rescue experiments can be performed by crossing the knockout to mice expressing tissue-specific transprovides an opportunity to verify the functional role(s) ascribed to various GPCRs. Our increasing ability to spa-genes. The creation of dopamine-deficient mice, noted above (166) , is but one example of how the large array V. SUMMARY of GPCR-related knockouts and transgenics can be combined to create new models of GPCR signaling and funcThe ability to manipulate the expression patterns of specific gene products in vivo has led to significant adtion. These types of studies will allow investigators in the future to apply genetic techniques to the study of vances in our understanding GPCR function and mechanism of action. In many cases, these techniques have pro-GPCR signal transduction that were previously possible only in more classical genetic model systems such as vided information that could not be achieved by standard pharmacological techniques. Additionally, these techyeast or Drosophila.
niques have also been used to effectively model various human disease processes, and thus provide a convenient IV. ADAPTING PHYSIOLOGICAL TECHNIQUES experimental platform. Recent advances in the techniques TO THE MOUSE of in vivo gene manipulation promise to advance our knowledge of GPCR function and will undoubtedly play a role in the design of future therapeutic approaches. The proliferation of techniques that allow the in vivo manipulation of GPCR gene expression has by necessity been followed by a corresponding proliferation in the REFERENCES methods to study them. Because most of these techniques involve mice or small rodents, this has resulted in the issues related to the differences between mice and hu-
